Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort.
COVID-19
Dyspnea
Outcomes
Patient
Predictors
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
13 Mar 2023
13 Mar 2023
Historique:
received:
28
11
2022
accepted:
28
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea. We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire. A total of 76 patients were included. Clinically meaningful dyspnea (baseline score > 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months. Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective management.
Sections du résumé
BACKGROUND
BACKGROUND
The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea.
METHODS
METHODS
We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire.
RESULTS
RESULTS
A total of 76 patients were included. Clinically meaningful dyspnea (baseline score > 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months.
CONCLUSIONS
CONCLUSIONS
Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective management.
Identifiants
pubmed: 36907855
doi: 10.1186/s12890-023-02376-w
pii: 10.1186/s12890-023-02376-w
pmc: PMC10008721
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2023. The Author(s).
Références
JAMA. 2022 Aug 16;328(7):676-678
pubmed: 35796131
JAMA Psychiatry. 2021 May 1;78(5):567-569
pubmed: 33599709
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
CMAJ. 2011 May 17;183(8):E487-94
pubmed: 21540166
ERJ Open Res. 2021 May 31;7(2):
pubmed: 34095290
ERJ Open Res. 2021 Sep 13;7(3):
pubmed: 34522693
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049168
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Lancet. 2021 Aug 28;398(10302):747-758
pubmed: 34454673
Respir Res. 2021 Aug 6;22(1):222
pubmed: 34362372
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
Chest. 1998 Mar;113(3):619-24
pubmed: 9515834
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Chest. 2022 Jan;161(1):54-63
pubmed: 34389297
Respir Res. 2021 Jul 8;22(1):202
pubmed: 34238283
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Front Physiol. 2022 Jul 06;13:917886
pubmed: 35874528
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
JACC Heart Fail. 2021 Dec;9(12):927-937
pubmed: 34857177
J Am Soc Echocardiogr. 2002 Feb;15(2):167-84
pubmed: 11836492
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 33008936
Thorax. 2021 Apr;76(4):402-404
pubmed: 33273023
N Engl J Med. 2003 Feb 20;348(8):683-93
pubmed: 12594312
J Cardiopulm Rehabil. 2005 Nov-Dec;25(6):370-7
pubmed: 16327533
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1120-8
pubmed: 9351611
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941